The estimated Net Worth of Thomas H Aasen is at least $3.93 Milhão dollars as of 12 December 2013. Thomas Aasen owns over 12,000 units of Cerecor Inc stock worth over $115,290 and over the last 20 years Thomas sold CERC stock worth over $3,811,900.
Thomas has made over 11 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Thomas sold 15,000 units of CERC stock worth $337,200 on 4 April 2014.
The largest trade Thomas's ever made was selling 60,000 units of Cerecor Inc stock on 13 August 2013 worth over $1,209,000. On average, Thomas trades about 7,671 units every 16 days since 2005. As of 12 December 2013 Thomas still owns at least 39,348 units of Cerecor Inc stock.
You can see the complete history of Thomas Aasen stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO, CA, 92121.
Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell, eCapital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.
Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.
Cerecor Inc executives and other stock owners filed with the SEC include: